BioCentury | Aug 13, 2007
Company News

Tikvah Therapeutics management update

...Neurology Hired: Jack Callicutt as VP and CFO, formerly SVP, CFO and accounting officer at Corautus Genetics Inc. WIR...
BioCentury | Feb 12, 2007
Company News

Corautus, Via Pharmaceuticals deal

...James Stewart and CMO Oye Olukotun. Lazard Freres advised Via, and Morgan Keegan advised VEGF. Corautus Genetics Inc....
BioCentury | Feb 9, 2007
Company News

VIA, Corautus to reverse-merge

VIA (San Francisco, Calif.) and VEGF will reverse-merge in a stock-for-stock transaction to form VIA Pharmaceuticals Inc., which is expected to trade on NASDAQ under the symbol VIAP. VIA's stockholders will own about 76% of...
BioCentury | Nov 13, 2006
Company News

Corautus management update

Corautus Genetics Inc. (VEGF), Atlanta, Ga. Business: Gene/Cell therapy, Cardiovascular Departing: Richard Otto as president and CEO, while remaining a director; and Robert Atwood as EVP and CFO, while remaining a director; Yawen Chiang as...
BioCentury | Nov 13, 2006
Clinical News

Vascular endothelial growth factor-2: Development discontinued

...using Stiletto endocardial direct injection catheter system from partner BSX to deliver the gene therapy. Corautus Genetics Inc....
BioCentury | Oct 16, 2006
Clinical News

Vascular endothelial growth factor-2: Final Phase IIb data

...direct injection catheter system to deliver the gene therapy. Boston Scientific Corp. (BSX), Natick, Mass. Corautus Genetics Inc....
BioCentury | Jul 17, 2006
Clinical News

Vascular endothelial growth factor-2: Phase IIb ongoing

...direct injection catheter system to deliver the gene therapy. Boston Scientific Corp. (BSX), Natick, Mass. Corautus Genetics Inc....
BioCentury | Jun 5, 2006
Clinical News

Vascular endothelial growth factor-2 regulatory update

...the Phase IIb GENASIS trial of VEGF-2 gene therapy to treat severe angina. In March, Corautus'...
...which the company said did not appear to be related to VEGF-2. In the trial, Corautus...
...trial had enrolled 295 out of 404 patients at the time of the suspension, and Corautus...
BioCentury | Apr 24, 2006
Company News

Corautus management update

Corautus Genetics Inc. (VEGF), Atlanta, Ga. Business: Gene/Cell therapy, Cardiovascular Promoted: Todd Stallings to VP of clinical operations from clinical trial manager for cardiovascular research WIR Staff...
BioCentury | Apr 17, 2006
Finance

Negative newsflow

...premature infants. FDA requests more information on the CMC section of the NDA. -41% $4.36 Corautus...
Items per page:
1 - 10 of 46
BioCentury | Aug 13, 2007
Company News

Tikvah Therapeutics management update

...Neurology Hired: Jack Callicutt as VP and CFO, formerly SVP, CFO and accounting officer at Corautus Genetics Inc. WIR...
BioCentury | Feb 12, 2007
Company News

Corautus, Via Pharmaceuticals deal

...James Stewart and CMO Oye Olukotun. Lazard Freres advised Via, and Morgan Keegan advised VEGF. Corautus Genetics Inc....
BioCentury | Feb 9, 2007
Company News

VIA, Corautus to reverse-merge

VIA (San Francisco, Calif.) and VEGF will reverse-merge in a stock-for-stock transaction to form VIA Pharmaceuticals Inc., which is expected to trade on NASDAQ under the symbol VIAP. VIA's stockholders will own about 76% of...
BioCentury | Nov 13, 2006
Company News

Corautus management update

Corautus Genetics Inc. (VEGF), Atlanta, Ga. Business: Gene/Cell therapy, Cardiovascular Departing: Richard Otto as president and CEO, while remaining a director; and Robert Atwood as EVP and CFO, while remaining a director; Yawen Chiang as...
BioCentury | Nov 13, 2006
Clinical News

Vascular endothelial growth factor-2: Development discontinued

...using Stiletto endocardial direct injection catheter system from partner BSX to deliver the gene therapy. Corautus Genetics Inc....
BioCentury | Oct 16, 2006
Clinical News

Vascular endothelial growth factor-2: Final Phase IIb data

...direct injection catheter system to deliver the gene therapy. Boston Scientific Corp. (BSX), Natick, Mass. Corautus Genetics Inc....
BioCentury | Jul 17, 2006
Clinical News

Vascular endothelial growth factor-2: Phase IIb ongoing

...direct injection catheter system to deliver the gene therapy. Boston Scientific Corp. (BSX), Natick, Mass. Corautus Genetics Inc....
BioCentury | Jun 5, 2006
Clinical News

Vascular endothelial growth factor-2 regulatory update

...the Phase IIb GENASIS trial of VEGF-2 gene therapy to treat severe angina. In March, Corautus'...
...which the company said did not appear to be related to VEGF-2. In the trial, Corautus...
...trial had enrolled 295 out of 404 patients at the time of the suspension, and Corautus...
BioCentury | Apr 24, 2006
Company News

Corautus management update

Corautus Genetics Inc. (VEGF), Atlanta, Ga. Business: Gene/Cell therapy, Cardiovascular Promoted: Todd Stallings to VP of clinical operations from clinical trial manager for cardiovascular research WIR Staff...
BioCentury | Apr 17, 2006
Finance

Negative newsflow

...premature infants. FDA requests more information on the CMC section of the NDA. -41% $4.36 Corautus...
Items per page:
1 - 10 of 46